CBD Shows Therapeutic Benefits Starting at 300 mg, With Strongest Evidence for Anxiety and Addiction | Research

The takeaway

A review of clinical studies found that oral CBD shows clear therapeutic effects at 300-400 mg/day, particularly for anxiety and addiction, with more marginal evidence for sleep, neurological disorders, and pain, while doses from 60-400 mg did not show increased side effects.

CBD consumers, clinicians considering CBD prescriptions, and regulators evaluating CBD products

300 mg/day therapeutic threshold

What the researchers found

Therapeutic benefits became clearly evident at doses of 300 mg or higher. At 300-400 mg, there is evidence for reduced anxiety and anti-addiction effects. More marginal benefits were found for insomnia, neurological disorders, and chronic pain. Increasing doses from 60 to 400 mg/day was not associated with more frequent adverse effects. Low-dose CBD products widely available as nutraceuticals lack strong evidence of efficacy.

Why it matters

Millions of people buy low-dose CBD products hoping for health benefits. This review suggests that most over-the-counter CBD products at typical doses (10-50 mg) may be below the therapeutic threshold, while higher doses show real promise for specific conditions.

The numbers in context

Therapeutic threshold at 300+ mg/day; anxiety and addiction evidence strongest; 60-400 mg/day dose range did not increase adverse effects; high-dose epilepsy treatment at 10-50 mg/kg already approved

How the study worked

Review of interventional studies measuring clinical efficacy and/or safety of oral CBD at doses up to 400 mg/day in adults. Excluded studies with THC content above 2.0%. Covered multiple health conditions including anxiety, addiction, sleep, pain, and neurological disorders.

What this study cannot tell us

Narrative review rather than systematic review. Many included studies had small sample sizes. CBD products varied in formulation and bioavailability across studies. Long-term safety data at higher doses remains limited.

How to read the evidence

Comprehensive review of clinical evidence, but narrative format and heterogeneous underlying studies limit certainty

When this study was published

2023 study

The bigger picture

The gap between what is available over the counter (typically 10-50 mg CBD) and what appears therapeutically effective (300+ mg) raises consumer protection questions. Many people may be spending money on doses too low to produce the benefits they seek.

Questions still open

Should CBD product labeling include information about therapeutic dose ranges? Could formulation improvements increase bioavailability of lower doses? Why do some individuals report benefits at doses below 300 mg?

Common questions

Does low-dose CBD (under 300 mg) actually work?

This review found that therapeutic benefits became clearly evident only at 300 mg or higher. Evidence for lower doses commonly found in OTC products is less robust.

Is higher-dose CBD safe?

In this review, increasing doses from 60 to 400 mg/day did not increase the frequency of adverse effects. However, very high doses used for epilepsy (10-50 mg/kg) can cause liver enzyme elevations and sedation.

Read the original research

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence.

Clinical and translational science, 16(1), 10-30

View on PubMed ↗Publisher’s paper ↗

Citation

Arnold, Jonathon C; McCartney, Danielle; Suraev, Anastasia; McGregor, Iain S. (2023). The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence.. Clinical and translational science, 16(1), 10-30. https://doi.org/10.1111/cts.13425